INCB28050 News
Most Popular INCB28050 Story
Lilly nabs rights to Incyte's RA drug for $755M
Eli Lilly is ending 2009 with its check book out and pen in hand. This morning Lilly announced that it will pay Incyte $90 million upfront and up to $665 million more for the worldwide rights to its Read more...
Latest Headlines
- December 21, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
